GlassScriptPhysician profile
Lisa M Smith
NPI 1295218238
$6,134.84
in general payments reported to CMS, 2019-2025
34 companies · $680 in 2025
The $680 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,963 · 2022: $990 · 2023: $1,351 · 2024: $1,151 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,181.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.45 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $590.50 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $564.29 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Nestle Healthcare Nutrition INC. | $514.28 | 2021-2023 | |
| Lilly USA, LLC | $448.11 | 2021-2025 | Mounjaro |
| Pfizer INC. | $373.71 | 2021-2025 | |
| Novo Nordisk INC | $278.06 | 2021-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $267.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.05 | 2021-2023 | Synjardy, Jardiance |
| Aimmune Therapeutics, INC. | $239.01 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $185.49 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $184.57 | 2021-2025 | Invega Sustenna, Xarelto, Invega Trinza |
| Sanofi-Aventis U.S. LLC | $152.67 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $151.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.95 | 2021-2025 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.